Because increased inflammatory markers and uric acid levels are associated with CED and possibly increased cardiovascular risk, the aim of this study was to examine the relationship of SUA, inflammation, and CED in postmenopausal women and to assess predictors of coronary Abstract-Uric acid is a risk factor for coronary artery disease in postmenopausal women, but the association with inflammation and coronary endothelial dysfunction (CED) is not well defined. The aim of this study was to determine the relationship of serum uric acid (SUA), inflammatory markers, and CED. In this prospective cohort study, SUA, high-sensitivity C-reactive protein levels, and neutrophil count were measured in 229 postmenopausal women who underwent diagnostic catheterization, were found to have no obstructive coronary artery disease, and underwent coronary microvascular function testing, to measure coronary blood flow response to intracoronary acetylcholine. The average age was 58 years (interquartile range, 52-66 years). Hypertension was present in 48%, type 2 diabetes mellitus in 5.6%, and hyperlipidemia in 61.8%. CED was diagnosed in 59% of postmenopausal women. Mean uric acid level was 4.7±1.3 mg/dL. Postmenopausal women with CED had significantly higher SUA compared with patients without CED (4.9±1.3 versus 4.4±1.3 mg/dL; P=0.02). There was a significant correlation between SUA and percent change in coronary blood flow to acetylcholine (P=0.009), and this correlation persisted in multivariable analysis. SUA levels were significantly associated with increased neutrophil count (P=0.02) and high-sensitivity C-reactive protein levels (P=0.006) among patients with CED, but not among those without CED. SUA is associated with CED in postmenopausal women and may be related to inflammation. These findings link SUA levels to early coronary atherosclerosis in postmenopausal women. (Hypertension. 2017;69:236-242.
C oronary artery disease (CAD) is a well-recognized leading cause of death in developed countries in both men and women. Premenopausal women have a lower cardiovascular risk when compared with men of the same age, and this is thought to be secondary to protective effects of estrogen. As estrogen levels decrease, cardiovascular risk may increase in postmenopausal women. 1, 2 Elevated uric acid levels and inflammatory markers have been associated with several cardiovascular risk factors, including hypertension, hyperlipidemia, obesity, and metabolic syndrome across the population but also in postmenopausal women. 3, 4 Serum uric acid (SUA) levels are increased in women undergoing both natural and surgical menopause even after adjustment for potential confounders. 5 Uric acid has, thus, been studied in postmenopausal women, and data show that the absence of estrogen may be associated with hyperuricemia. 6 In addition, higher levels of uric acid have been associated with increased coronary artery calcium deposits and progression of CAD, independent of other cardiovascular risk factors in postmenopausal women. 7 Uric acid has also been identified as an independent predictor of cardiovascular events. 7, 8 This may be secondary to inflammation as evidenced by increased inflammatory markers and oxidative stress and decreased release of endothelial nitric oxide and evolution of endothelial dysfunction. 7, 9, 10 Interestingly, uric acid levels even at the upper limit of normal have been shown to be associated with increased cardiovascular risk. [11] [12] [13] [14] [15] [16] The mechanism explaining this association of uric acid and cardiovascular disease in patients with coronary endothelial dysfunction (CED) is poorly understood. Endothelial dysfunction, characterized by reduced nitric oxide activity, is an early phase of atherosclerosis and a predictor of cardiovascular events. [17] [18] [19] [20] [21] [22] [23] [24] [25] Preliminary data suggest that peripheral endothelial dysfunction may be associated with elevated uric acid levels; however, these findings are inconsistent. [24] [25] [26] [27] How uric acid may contribute to CED is unknown.
The association of elevated uric acid levels and peripheral endothelial dysfunction, CAD, and all-cause mortality seems to be more pronounced in postmenopausal women.
events in this population. We hypothesized that uric acid and inflammation were associated with endothelial dysfunction and adverse outcomes.
Methods

Patient Population
Consecutive patients referred to Mayo Clinic between January 1992 and August 2012 for cardiac catheterization with no evidence of significant CAD on initial angiography were enrolled. All patients had blood work that included measurement of C-reactive protein; complete blood count with differential, basic chemistry panel; and uric acid level. We excluded any patient who was not a postmenopausal female or had not completed baseline laboratory testing and index angiography with complete acetylcholine study. On enrollment, all patients completed a standardized validated questionnaire to assess baseline characteristics. 21, 30, 31 Menopausal status was assessed on enrollment via questionnaire and based on primary physician diagnosis. A total of 229 subjects who underwent comprehensive coronary endothelial function assessment and basic laboratory assessment were analyzed. All patients had provided informed consent as part of study enrollment, but there was no specific consent obtained to analyze uric acid specifically. Only postmenopausal women with complete laboratory testing and index angiography with complete acetylcholine study were included. Patients with history of percutaneous coronary intervention, coronary artery bypass graft surgery, unstable angina pectoris, valvular heart disease, peripheral vascular disease, or known congestive heart failure were excluded from the study. The study was approved by the Mayo Clinic Institutional Review Board, and all patients provided informed consent.
Coronary Endothelial Function Assessment
Endothelium-dependent coronary vasoreactivity was assessed according to the standardized protocol as previously described. 21, 31, 32 The Doppler guidewire was advanced within the coronary infusion catheter and placed in the mid-left anterior descending coronary artery. Acetylcholine was administered in the left anterior descending artery at incremental doses for 3 minutes each with increasing concentrations. During each infusion, Doppler measurements, hemodynamic tracings, and coronary angiogram were recorded to be subsequently analyzed by a blinded, independent investigator. Coronary artery diameter was measured by having an investigator measure the segment 6 mm distal to the Doppler wire tip using a computer-based image system. The percent change in coronary blood flow (CBF) in response to acetylcholine was indicative of endothelium-dependent coronary flow reserve. CED was defined as <50% increase in CBF with acetylcholine. 21, 33, 34 
Subsequent Evaluation
All patients received a standardized questionnaire for assessment of their overall health several years after their index coronary angiogram and endothelial function study. The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events (MACE), including stroke, rehospitalization, myocardial infarction, or death after a median follow-up of 6.3 years (interquartile range, 3.5-10.7 years). Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
Statistical Analysis
All data are displayed as mean±SD. Variables that have skewed distribution are reported as median with first and third quartiles listed in parenthesis. Demographic and baseline clinical data were compared using Fisher exact test, ANOVA, and Wilcoxon tests for continuous data and Pearson χ 2 test for categorical data after adjustment for potential confounders, including traditional cardiovascular risk factors.
Results
Baseline Characteristics
A total of 229 postmenopausal women without epicardial stenosis on coronary angiography underwent microvascular function testing with graded infusion of acetylcholine (Table) . Average age was 58 years (interquartile range, 52-66 years). Hypertension was present in 48%, type 2 diabetes mellitus in 5.6%, and hyperlipidemia in 61.8%. Mean uric acid level was 4.7±1.3 mg/dL.
CED was diagnosed in 59% of postmenopausal women on invasive acetylcholine testing. There was no significant difference in follow-up duration between patients with and without CED (P=0.96).
CBF and Uric Acid
Patients with CED had significantly higher levels of uric acid when compared with patients without CED (4.9±1.3 versus 4.4±1.3 mg/dL; P=0.03). There was a significant correlation between SUA level and percent change in CBF with acetylcholine (P=0.009; Figure 1 ).
In a linear regression model, higher SUA levels were significantly associated with higher neutrophil counts (P=0.01; Figure 2 ) and higher high-sensitivity C-reactive protein (hsCRP) levels (P=0.006) in patients with CED ( Figure 3 ). After adjustment for history of current estrogen use, glomerular filtration rate, hypertension, and body mass index, SUA remained significantly associated with CED (P=0.02). Neutrophil count and hsCRP were not significantly associated with CED.
CBF and Inflammatory Markers
In a linear regression model, increasing uric acid levels were significantly associated with increased neutrophil count (P=0.01; Figure 2 ) and increased hsCRP levels (P=0.006; Figure 3 ) in patients with CED. Uric acid was not associated with increased levels of inflammatory markers in patients without CED (P>0.05). Higher SUA levels were associated 
Major Adverse Cardiovascular Events
Patients were followed for a median of 7 years (interquartile range, 4-11 years) for the development of MACE, which included stroke, cardiovascular death, myocardial infarction, and cardiovascular hospitalization. There were a total of 25 MACE, 16 occurring in patients with CED on baseline acetylcholine study and 9 in patients without CED. Baseline uric acid levels were significantly higher in patients who developed MACE than in patients who did not (5. Figure 4 ). When stratifying by patients with and without CED, uric acid levels were only significantly associated with MACE in patients with CED. Uric acid was an independent predictor of MACE after adjustment for potential confounders, including age, hypertension, diabetes mellitus, hyperlipidemia, body mass index, and estrogen (likelihood ratio, 8.9; P=0.003). Given potential association of lipid levels and fasting blood glucose, a separate multivariable regression adjusting for age, hypertension, glucose, uric acid, body mass index, high-density lipoprotein, low-density lipoprotein, triglycerides, estrogen use, and antihypertensive use showed that uric acid remained an independent predictor of MACE (likelihood ratio, 4.3; P=0.04).
Discussion
This study demonstrates an association between SUA, CED, inflammatory markers, and cardiovascular outcomes. We have 3 main findings. First, CED in postmenopausal women is independently associated with increased SUA levels after adjustment for traditional risk factors. Second, higher uric acid levels were associated with higher levels of inflammatory markers in patients with CED, and higher inflammatory markers were in turn associated with a reduced response of CBF to acetylcholine. Third, baseline uric acid levels were higher in patients who developed MACE on follow-up, and uric acid was an independent predictor of MACE after adjusting for potential confounders. Higher uric acid levels at baseline may play a role in the development of adverse cardiovascular outcomes, although the mechanisms for this are unclear. These findings suggest that SUA levels are associated with CED and potentially progression of atherosclerosis mediated by uric acid and inflammation.
CED is increasingly recognized as an initial predisposing step for the development of atherosclerosis. Recognition of risk factors for early coronary atherosclerosis and CED can be important in identifying and treating vulnerable patients who might develop CAD. 17, 18, 20, 35 Although uric acid is a recognized risk factor in the development of cardiovascular disease, the mechanism is not well understood.
Uric Acid and Cardiovascular Risk Factors
Several studies have suggested that uric acid is associated with traditional cardiovascular risk factors and MACE, and several mechanisms have been postulated to explain these associations, including inflammatory and vascular changes in the microcirculation, endothelial dysfunction, and dysregulation of glucose uptake. 9, 10, 36, 37 Adverse outcomes of uric acid are independent of crystal formation, and so even normal levels of uric acid may be associated with adverse cardiovascular events. Several studies have shown that uric acid levels at the upper limit of normal can be associated with cardiovascular risk factors and mortality and suggest that a lower threshold may be considered to prevent cardiovascular events. 11, 14, 15 SUA has also been associated with endothelial dysfunction in several studies. Acikgoz et al 38 found that SUA levels were higher in patients with microvascular angina and that SUA levels were predictive of carotid atherosclerosis. Increased hsCRP levels and reduced flow-mediated vasodilation have also been reported in patients with higher uric acid levels. 39 This association between elevated uric acid levels and reduced flow-mediated vasodilation has been corroborated by other studies. 40, 41 This study, thus, extends these previous observations and demonstrates for the first time the relationship between SUA and coronary endothelial function.
Uric acid levels also may be associated with hypertension, which in turn has been associated with endothelial dysfunction. Zoccali et al 42 studied a cohort of patients with untreated essential hypertension reporting that uric acid levels were associated with endothelial dysfunction even after adjustment for potential confounders. The role of hypertension is unclear, but given that hypertension may be associated with both microvascular dysfunction and uric acid levels, we adjusted for both hypertension and antihypertensive use and found that uric acid remained an independent predictor of major adverse cardiovascular outcomes in this population. In a separate study of patients with untreated essential hypertension, inflammation was implicated as a potential key factor mediating the endothelial-renal function link. 43 Treatment of hyperuricemia with allopurinol has been associated with improved cardiovascular outcomes, further supporting our findings. [44] [45] [46] [47] In a recent large prospective case-matched cohort study of patients with gout, urate-lowering therapy was found to improve overall cardiovascular outcomes. 47 Colchicine has also been shown to result in significant reduction in cardiovascular mortality in patients with gout.
48,49
Uric Acid and CVD in Women
Several studies have alluded to a sex-specific association between uric acid levels, inflammatory markers, early atherosclerosis, and cardiovascular disease. Data suggest that the association between uric acid and cardiovascular risk factors and cardiovascular disease may be particularly prominent in postmenopausal women, further supporting our findings that CED is associated with increased uric acid levels and inflammation in postmenopausal women. 5, [50] [51] [52] [53] Hyperuricemia has been independently associated with noninvasive peripheral endothelial dysfunction in postmenopausal women. 40 Elevated uric acid levels have also been independently associated with increased coronary artery calcification in postmenopausal women without known cardiovascular risk factors and increased incident risk of MACE.
7,8
Potential Mechanisms
There is a growing body of evidence suggesting an association between increased uric acid levels and postmenopausal status and a causal link to increased cardiovascular risk in postmenopausal women. Endogenous estradiol plays a role in preserving endothelial function and in lowering SUA level independent of cardiovascular risk factors, and with menopause, decreased estrogen levels and increased SUA levels may promote endothelial dysfunction and development of cardiovascular disease. 5, [54] [55] [56] Although the mechanism linking uric acid and cardiovascular disease has yet to be fully understood, it has been postulated that decreased estrogen levels may lead to increased uric acids levels, which in turn may cause endothelial dysfunction, predisposing patients to the development of cardiovascular disease. 57 Inflammation also plays a key role in the link between uric acid and endothelial dysfunction. [58] [59] [60] In this study, we found that elevated inflammatory markers, including hsCRP and neutrophil count, were associated with reduced percent change CBF with acetylcholine. In addition, higher SUA levels were significantly associated with increased hsCRP and MACE in several studies of patients with CED, suggesting an association between inflammation and endothelial dysfunction. [61] [62] [63] These findings are supported by previous data linking elevated inflammatory markers to elevated uric acid levels. 64 Data suggest that uric acid may induce both endothelial dysfunction and vessel inflammation, which concomitantly may lead to accelerated atherosclerosis, likely explaining the increased MACE seen in patients with higher uric acid levels and CED. 39, 64, 65 Uric acid seems to exert a proinflammatory effect on endothelial cells, causing reduced nitric oxide bioavailability, and vascular smooth muscle cells, increasing chemokine and cytokine expression. 66, 67 SUA levels have also been suggested to be predictive of cardiovascular disease because of its sensitivity for underlying inflammation and remodeling within the arterial vessel wall. 68, 69 Last, SUA has been shown to be linearly related with the activity of xanthine oxidase. Increased xanthine oxidase enzyme activity may be associated with a corresponding increased production of free oxygen radicals, potentially activating the atherosclerotic process. 70 This is further supported by studies showing that xanthine oxidase inhibition is associated with improved endothelial function, cardiovascular risk, and plaque progression in preclinical and clinical studies. [71] [72] [73] [74] [75] [76] Thus, xanthine oxidase activity and increased oxygen free radicals may play a key role in initiation and progression of atherosclerosis, even independent of uric acid. Our findings from this study demonstrating an association between increased inflammatory markers, uric acid levels, and impaired endothelial dysfunction are, thus, consistent with these observations.
60
Limitations
The findings are based on cross-sectional data at initial presentation. A temporal association between uric acid and development of endothelial dysfunction cannot be inferred with certainty. Our data on outcomes in these patients were obtained via a questionnaire-based method, which inherently could be biased and cause an overall underestimation of the number of events in each group. In addition, we do not have data describing the length of antihypertensive therapy in these patients, and this could have a potential effect on endothelial function. To best address this, we have adjusted for use of antihypertensive medications in our analysis. Last, menopausal status was assessed by questionnaire, and thus hormonal levels are not available.
Conclusions
Increased SUA levels are associated with CED and increased inflammatory markers in postmenopausal women. Detection of markers of inflammation, including uric acid, may be useful in understanding the mechanism and predicting progression of patients with nonobstructive CAD and atherosclerosis. Moreover, further investigation is necessary to explore the use of lowering uric acid levels in risk factor modification and attenuation of nonobstructive coronary disease and atherosclerosis.
Perspectives
In postmenopausal women with nonobstructive women, we find that uric acid levels are higher in those with elevated inflammatory markers and coronary microvascular dysfunction. Moreover, SUA levels seemed to be associated with increased MACE. Further investigation is necessary to explore the role of uric acid and uric acid lowering therapies in management of cardiovascular risk in postmenopausal women.
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